• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patterns of Penetrance and Expressivity of Long-Term Outcomes in Classic Galactosemia.经典型半乳糖血症长期预后的外显率和表现度模式
J Inherit Metab Dis. 2025 May;48(3):e70020. doi: 10.1002/jimd.70020.
2
Effect of genotype on galactose-1-phosphate in classic galactosemia patients.经典型半乳糖血症患者基因型对 1-磷酸半乳糖的影响。
Mol Genet Metab. 2018 Nov;125(3):258-265. doi: 10.1016/j.ymgme.2018.08.012. Epub 2018 Aug 23.
3
Transient developmental delays in infants with Duarte-2 variant galactosemia.患有 2 型达尔特变异半乳糖血症婴儿的短暂性发育迟缓。
Mol Genet Metab. 2021 Sep-Oct;134(1-2):132-138. doi: 10.1016/j.ymgme.2021.07.009. Epub 2021 Jul 30.
4
Classic Galactosemia and Clinical Variant Galactosemia经典型半乳糖血症和临床变异型半乳糖血症
5
Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia.隐匿性残留 GALT 活性是经典半乳糖血症学龄儿童学业成绩的潜在修饰因子。
J Inherit Metab Dis. 2013 Nov;36(6):1049-61. doi: 10.1007/s10545-012-9575-x. Epub 2013 Jan 15.
6
Galactosemia: when is it a newborn screening emergency?半乳糖血症:何时属于新生儿筛查急症?
Mol Genet Metab. 2012 May;106(1):7-11. doi: 10.1016/j.ymgme.2012.03.007. Epub 2012 Mar 21.
7
A galactose-1-phosphate uridylyltransferase-null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue-specific and longitudinal differences in galactose metabolism.经典半乳糖血症的半乳糖-1-磷酸尿苷酰转移酶缺失大鼠模型模拟了相关的患者结局,并揭示了半乳糖代谢在组织特异性和纵向方面的差异。
J Inherit Metab Dis. 2020 May;43(3):518-528. doi: 10.1002/jimd.12205. Epub 2019 Dec 29.
8
Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia.新型基于 mRNA 的疗法可降低经典半乳糖血症小鼠模型中的毒性半乳糖代谢物并克服对半乳糖的敏感性。
Mol Ther. 2020 Jan 8;28(1):304-312. doi: 10.1016/j.ymthe.2019.09.018. Epub 2019 Sep 19.
9
Restoring galactose metabolism without restoring GALT rescues both compromised survival in larvae and an adult climbing deficit in a GALT-null D. Melanogaster model of classic galactosemia.在缺乏 GALT 的情况下,恢复半乳糖代谢而不恢复 GALT,可挽救经典半乳糖血症的 GALT 缺失 D. melanogaster 模型中幼虫的生存能力受损和成年后攀爬能力缺陷。
J Inherit Metab Dis. 2024 Sep;47(5):991-1000. doi: 10.1002/jimd.12774. Epub 2024 Jul 3.
10
Biochemical changes and clinical outcomes in 34 patients with classic galactosemia.34 例经典半乳糖血症患者的生化变化和临床转归。
J Inherit Metab Dis. 2018 Mar;41(2):197-208. doi: 10.1007/s10545-018-0136-9. Epub 2018 Jan 19.

本文引用的文献

1
Health and well-being of maturing adults with classic galactosemia.患有典型半乳糖血症的成年人的健康与福祉。
J Inherit Metab Dis. 2025 Jan;48(1):e12786. doi: 10.1002/jimd.12786. Epub 2024 Aug 14.
2
Brain function in classic galactosemia, a galactosemia network (GalNet) members review.经典型半乳糖血症中的脑功能,半乳糖血症网络(GalNet)成员综述。
Front Genet. 2024 Feb 15;15:1355962. doi: 10.3389/fgene.2024.1355962. eCollection 2024.
3
Increased Risk of Long-Term Disabilities Following Childhood Bacterial Meningitis in Sweden.瑞典儿童细菌性脑膜炎后长期残疾风险增加。
JAMA Netw Open. 2024 Jan 2;7(1):e2352402. doi: 10.1001/jamanetworkopen.2023.52402.
4
Long-term complications in classic galactosemia are not progressive.经典半乳糖血症的长期并发症并非进行性的。
Mol Genet Metab. 2023 Nov;140(3):107708. doi: 10.1016/j.ymgme.2023.107708. Epub 2023 Oct 11.
5
A multinational study of acute and long-term outcomes of Type 1 galactosemia patients who carry the S135L (c.404C > T) variant of GALT.一项关于携带 GALT 基因 S135L(c.404C>T) 变异的 1 型半乳糖血症患者急性和长期结局的多国研究。
J Inherit Metab Dis. 2022 Nov;45(6):1106-1117. doi: 10.1002/jimd.12556. Epub 2022 Sep 26.
6
Pathophysiology of long-term complications in classic galactosemia: What we do and do not know.经典半乳糖血症长期并发症的病理生理学:我们所知与未知。
Mol Genet Metab. 2022 Sep-Oct;137(1-2):33-39. doi: 10.1016/j.ymgme.2022.07.005. Epub 2022 Jul 9.
7
Deep phenotyping classical galactosemia: clinical outcomes and biochemical markers.经典型半乳糖血症的深度表型分析:临床结局和生化标志物
Brain Commun. 2020 Jan 29;2(1):fcaa006. doi: 10.1093/braincomms/fcaa006. eCollection 2020.
8
The natural history of classic galactosemia: lessons from the GalNet registry.经典半乳糖血症的自然病程:GalNet 注册研究的启示。
Orphanet J Rare Dis. 2019 Apr 27;14(1):86. doi: 10.1186/s13023-019-1047-z.
9
Biochemical changes and clinical outcomes in 34 patients with classic galactosemia.34 例经典半乳糖血症患者的生化变化和临床转归。
J Inherit Metab Dis. 2018 Mar;41(2):197-208. doi: 10.1007/s10545-018-0136-9. Epub 2018 Jan 19.
10
Rigor of non-dairy galactose restriction in early childhood, measured by retrospective survey, does not associate with severity of five long-term outcomes quantified in 231 children and adults with classic galactosemia.通过回顾性调查衡量的婴幼儿时期非乳制品半乳糖限制的严格程度,与 231 名经典半乳糖血症患儿和成人中量化的 5 种长期结局的严重程度无关。
J Inherit Metab Dis. 2017 Nov;40(6):813-821. doi: 10.1007/s10545-017-0067-x. Epub 2017 Jul 10.

经典型半乳糖血症长期预后的外显率和表现度模式

Patterns of Penetrance and Expressivity of Long-Term Outcomes in Classic Galactosemia.

作者信息

Smith Nicole H, Garrett Olivia S, Hendrickson Emma, Druss Jared J, Fridovich-Keil Judith L

机构信息

Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.

出版信息

J Inherit Metab Dis. 2025 May;48(3):e70020. doi: 10.1002/jimd.70020.

DOI:10.1002/jimd.70020
PMID:40174935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11970356/
Abstract

Long-term complications are common among patients with classic galactosemia (CG) and show both reduced penetrance and variable expressivity. Overall prevalence rates for complications in cognitive, motor, and speech/voice/language outcomes among US and European cohorts are known. However, age at presentation, whether these complications cluster, and what factors might associate with penetrance remain unknown. These gaps in knowledge limit prognostic accuracy for young patients and leave open the question of whether complications in different outcome domains may have shared modifiers. Here we addressed these questions using data from medical records and family survey responses from 164 patients and 77 controls. We found that for cases who experienced long-term complications, the median age at presentation of challenges in cognitive outcome was about 5 years, in motor outcome was about 3 years, and in speech/voice/language outcome was about 2 years. We also found highly significant clustering of complications in these three domains. Finally, we tested six factors for possible association with penetrance: history of severe neonatal symptoms, GALT genotype and predicted residual GALT activity, days of neonatal milk exposure, rigor of non-dairy galactose restriction in early childhood, peak red blood cell (RBC) galactose-1P level in infancy, and baseline RBC galactose-1P level in early childhood. Of these, only history of severe neonatal brain-related symptoms consistently associated with higher penetrance, and only detectable predicted residual GALT activity consistently associated with lower penetrance. Combined, these results substantially extend what is known about the natural history of long-term complications in CG.

摘要

长期并发症在经典型半乳糖血症(CG)患者中很常见,且表现出较低的外显率和可变的表达性。美国和欧洲队列中认知、运动及言语/语音/语言方面并发症的总体患病率是已知的。然而,发病年龄、这些并发症是否聚集以及哪些因素可能与外显率相关仍不清楚。这些知识空白限制了对年轻患者的预后准确性,并留下了不同结局领域的并发症是否可能有共同调节因素的问题。在这里,我们使用来自164例患者和77例对照的病历数据和家庭调查回复来解决这些问题。我们发现,对于经历长期并发症的病例,认知结局出现挑战的中位发病年龄约为5岁,运动结局约为3岁,言语/语音/语言结局约为2岁。我们还发现这三个领域的并发症高度聚集。最后,我们测试了六个可能与外显率相关的因素:严重新生儿症状史、GALT基因型和预测的残余GALT活性、新生儿期牛奶暴露天数、幼儿期非乳制品半乳糖限制的严格程度、婴儿期红细胞(RBC)半乳糖-1-磷酸峰值水平以及幼儿期RBC半乳糖-1-磷酸基线水平。其中,只有严重的新生儿脑相关症状史始终与较高的外显率相关,只有可检测到的预测残余GALT活性始终与较低的外显率相关。综合来看,这些结果极大地扩展了我们对CG长期并发症自然史的认识。